148 CHAPTER 8 REFERENCES 1. Ogilvie I, Newton N, Welner S, Cowell W, Lip G. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med. 2010;123(7):638-645.e4. 2. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: Perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013;8(5):e63479. 3. Camm AJ, Pinto FJ, Hankey GJ, Andreotti F, Hobbs FDR. Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: Barriers to and strategies for optimal implementation. Europace. 2015;17:1007–17. 4. Sterne J, Bodalia P, Bryden P, Davies P, López-López J, Okoli G, et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: Systematic review, network metaanalysis and cost-effectiveness analysis. Health Technol Assess. 2017;21(9):1–386. 5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Eng J Med. 2009;361(12):1139–51. 6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Eng J Med. 2011;365(10):883–91. 7. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial Fibrillation. N Engl J Med. 2011;365(11):981–92. 8. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Eng J Med. 2013;369(22):2093–104. 9. Steinberg B, Washam J. Appropriate dosing of nonvitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation. Trends in Cardiovasc Med. 2017;27(8):567–72. 10. Pokorney S, Peterson E, Piccini J. When less is not more. J Am Coll Cardiol. 2017;69(23):2791– 3. 11. van Vugt S, Brouwer M, Verheugt F. Off-label use of non-vitamin K antagonist oral anticoagulants. J Am Coll Cardiol. 2017;69:2577–8. 12. Weitz J, Eikelboom J. Appropriate apixaban dosing: Prescribers take note. JAMA Cardiol. 2016;1(6):635–6. 13. Shen NN, Zhang C, Hang Y, Li Z, Kong LC, Wang N, et al. Real-world prevalence of direct oral anticoagulant off-label doses in atrial fibrillation: An epidemiological meta-analysis. Front Pharmacol. 2021;12:581293. 14. Santos J, António N, Rocha M, Fortuna A. Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: A systematic review. Br J Clin Pharmacol. 2020;86:533–47. 15. Beasley B, Unger E, Temple R. Anticoagulant options - Why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011;364(19):1788–90. 16. Sang C, Chen J, Sun J, Lai Y, Liu X, Zhu W. Off-label underdosing of four individual NOACs in patients with nonvalvular atrial fibrillation: A systematic review and meta-analysis of observational studies. Eur J Clin Invest. 2022;(10):e13819 17. Kong X, Zhu Y, Pu L, Meng S, Zhao L, Zeng W, et al. Efficacy and safety of non-recommended dose of new oral anticoagulants in patients with atrial fibrillation: A systematic review and meta-analysis. Front Cardiovasc Med. 2021;8:774109. 18. Caso V, de Groot JR, Sanmartin Fernandez M, Segura T, Blomström-Lundqvist C, Hargroves D, et al. Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: A systematic review and metaanalysis. Heart. 2023;109:178–85.
RkJQdWJsaXNoZXIy MTk4NDMw